Heart disease in the US (source, US Centers for Disease Control and Prevention)
Heart disease is the number one cause of death wordwide1. Early, accurate CVD risk assessment is part of established clinical care for primary prevention and disease management.
2. Sachdeva, A., et al., Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J, 2009. 157(1): 111-117 e2.
Our CE-marked AXINON® lipoFIT® test* provides more precise information than the standard cholesterol test.
It measures concentration, size and distribution of the lipoprotein particles that carry cholesterol, as well as the quantity of triglycerides, cholesterol and phospholipids.
*AXINON® lipoFIT® is available as CE-marked in the EU and as a Research-Use-Only product in the United States. This product has not yet been cleared by the US Food and Drug Administration.
Nuclear magnetic resonance (NMR) spectroscopy is a proven and highly accurate test technology that assesses a variety of compounds at a molecular level.
Our FDA-cleared AXINON® System is the core technology platform we use to develop diagnostic tests for illnesses stemming from metabolic dysfunction, including chronic heart, kidney and liver diseases.
This system incorporates diagnostic testing algorithms into nuclear magnetic resonance (NMR) spectroscopy for precise results.
To date, more than 3 million tests have been performed worldwide using Numares technology.
Laboratories providing Numares advanced lipoprotein testing:
*For Research Use only in the United States. Numares products haven't yet been approved or cleared by the US Food and Drug Administration; the products are not yet available for sale in the US. However, the AXINON® LDL-p Test System and AXINON®System are FDA-cleared and available for sale.